{"paper_id":"bb3d14a2-96df-4986-a611-a9a8636acf33","body_text":"Pharmaceutical care in the treatment of menstrual cycle disorders among women of reproductive age: rational choice and use of drugs\nDOI:\nhttps://doi.org/10.32352/0367-3057.4.23.09Keywords:\nmenstrual cycle, women, pharmaceutical care, drug interactionAbstract\nIn the structure of gynecological diseases, menstrual cycle disorders are for up to 60% and are the most common problem among women of reproductive age. Disorders of menstrual function can be caused by hormonal imbalance, endocrine system diseases, stress, hypovitaminosis, and excessive physical exertion. Changing of the menstrual cycle phases in the future may prevent normal fertilization, therefore it is necessary to receive appropriate pharmacotherapy in a timely manner, which is aimed to correct the main and accompanying pathological conditions for normalizing the reproductive function of women.\nThe aim of the work – justification of the feasibility of developing pharmaceutical care for menstrual cycle disorders among women of reproductive age.\nThe pharmacotherapy courses of 133 women aged 18 to 40 who were consulted by gynecologist at the «Kyiv City Maternity Hospital No. 5» and had menstrual cycle disorders were analyzed. Then, a questionnaire was carried out, in which 115 women took part.\nIt was established that the pharmacotherapy courses that included more than 5 drugs and contained hormonal agents had high risks of interaction. In addition, herbal remedies, biologically active supplements, and vitamins are often used to treat menstrual disorders.\nAccording to the results of a sociological study, a high frequency of menstrual cycle disorders was found among women of reproductive age, the manifestations of which were delayed menstruation (66.6%), the appearance or intensification of a pain syndrome (52.2%), a change in menstruation (27.8%), etc. It has been established that more than 40% of women apply to self-prescription and self-treatment of menstrual cycle disorders. While 12% do not use the drugs for the normalization of menstrual function that was recommended by the doctor. In addition, 20 women who received treatment noted the appearance of side effects, such as headache, fatigue, irritability, changes in body weight, and swelling.\nThe interaction between the gynecologist-pharmacist-patient is important to ensure rational and safe pharmacotherapy in the treatment of menstrual cycle disorders among women. The pharmacist, through the provision of pharmaceutical care, implements special knowledge of clinical pharmacology regarding the peculiarities of the interaction of drugs, the regimen of taking medicine, and the prevention of adverse reactions that may increase the effectiveness of the treatment of menstrual disorders among women.\nReferences\nKwak Y., Kim Y., Baek K. A. Prevalence of irregular menstruation according to socioeconomic status: A population-based nationwide cross-sectional study // PloS one. – 2019. – V. 14, N 3. – Р. e0214071. https://doi.org/10.1371/journal.pone.0214071\nMadaminov M. Causes, symptoms, classification, treatment methods of menstrual cycle disorder // Sci. Innovation. – 2022 – V. 7, N 1. https://doi.org/10.5281/zenodo.7296389\nHuhmann K. Menses Requires Energy: A Review of How Disordered Eating, Excessive Exercise, and High Stress Lead to Menstrual Irregularities // Clin. Therapeutics. – 2022 – V. 42, N 3. – Р. 401–407. https://doi.org/10.1016/j.clinthera.2020.01.016\nDemir O., Sal H., Comba C. Triangle of COVID, anxiety and menstrual cycle // J. Obstetrics Gynecology. – 2021 – V. 41, Iss. 8. – P. 1257–1261. https://doi.org/10.1080/01443615.2021.1907562\nRodríguez Quejada L., Toro Wills M. F., Martínez-Ávila M. C., Patiño-Aldana A. F. Menstrual cycle disturbances after COVID-19 vaccination // Women's Health. – 2022. – V. 18. https://doi.org/10.1177/17455057221109375\nLebar V., Laganà A. S., Chiantera V. et al. The Effect of COVID-19 on the menstrual cycle: asystematic review // J. Clin. Med. ‒ 2022. – V. 11, Iss. 13. https://doi.org/10.3390/jcm11133800\nBurlaka O. V., Vahnier V. O. Pytannia reproduktyvnoho zdorovia zhinok viiskovosluzhbovtsiv v aspekti stres-asotsiiovanykh dyshormonalnykh porushen // Viiskova medytsyna Ukrainy. – 2021. – T. 19, № 4. – S. 58–63. https://doi.org/10.32751/2663-0761-2019-04-08\nKolisova S. E. Do pytannia patohenezu porushennia menstrualnoho tsyklu// Klin. eksperyment. patolohiia. – 2015. – T. 54, № 4. – S. 66–68.\nPodolskyi V. V., Kozar Ya. V. Porushennia reproduktyvnoho zdorovia u zhinok fertylnoho viku yododefitsytnykh rehioniv Ukrainy // Akt. pytannia pediatrii, akusherstva ta hinekolohii. – 2009. – № 1. – S. 37–40. https://doi.org/10.11603/24116-4944.2009.1.9654\nSaei Ghare Naz M., Rostami Dovom M., Ramezani Tehrani F. The menstrual disturbances in endocrine disorders: anarrative review // Int. J. Endocrinol. Metab. – 2020. – V. 18, N 4. – Р. e106694. https://doi.org/10.5812/ijem.106694\nMalanchuk O., Sharhorodska Ye., Shkolnyk O. Otsinka faktoriv ryzyku perynatalnoi patolohii u zhinok iz porushenniam menstrualnoi funktsii // Bukovynskyi med. visn. – 2021. – T. 98, № 2. – S. 75–81. https://doi.org/10.24061/2413-0737.XXV.2.98.2021.12\nBahrami A., Avan A., Sadeghnia H. R. et al. High dose vitamin D supplementation can improve menstrual problems, dysmenorrhea, and premenstrual syndrome in adolescents // Gynecol. Endocrinol. – 2018. – V. 34, N 8– P. 659–663. https://doi.org/10.1080/09513590.2017.1423466\nAguilar-Aguilar E. Menstrual disorders: what we know about dietary-nutritional therapy // Nutricion Hospitalaria. – 2021. – N 2. – P. 52–56. https://doi.org/10.20960/nh.03358\nTiong H. Y., Huang P., Xiong S. et al. Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models // Mol. Pharm. – 2014. – V. 11, N 7. – P. 1933‒1948. https://doi.org/10.1021/mp400720w\nZhabitska L. A. Syndrom polikistoznykh yaiechnykiv: indyvidualizovanyi pidkhid do likuvannia (ohliad literatury) // Reproduktyvna endokrynolohiia. – 2020. – T. 54, № 4. – S. 89–94.\nDrugBank. Levothyroxine. – URL: https://www.drugbank.ca/drugs/DB00451\nWen Z. P., Yang R. X., Feng X. J. et al. The interaction of aspirin and ethinylestradiol in human liver microsomes // Eur. J. Clin. Pharmacol. – 2009. – V. 65, N 10. – P. 983–990. https://doi:10.1007/s00228-009-0683-3\nVan der Pas R., Hofland L. J., Hofland J. et al. Fluconazole inhibits human adrenocortical steroidogenesis in vitro // J. Endocrinol. – 2012. – V. 215, N 3. – P. 403–412. https://doi.org/10.1530/JOE-12-0310\nLiu H. C., Goldenberg A., Chen Y. et al. Molecular Properties of Drugs Interacting with SLC22 Transporters OAT1, OAT3, OCT1, and OCT2: A Machine-Learning Approach // J. Pharmacol. Exp. Ther. – 2016. – V. 359, N 1. – P. 215–229. https://doi.org/10.1124/jpet.116.232660\nNational Institute for Health and Care Excellence. Acne vulgaris: management / Clinical guideline [CG 17]. ‒ 2018. – URL: https://www.nice.org.uk/guidance/cg17\nAlkoudsi K. T., Al-Qudah R., Basheti I. A. Assessing the effectiveness of a pharmaceutical care service on the quality of life of women with polycystic ovarian syndrome living in war and non-war countries // Journal of Evaluation in Clinical Practice. – 2020. – V. 26, N 5. – Р. 1467–1477. https://doi.org/10.1111/jep.13310\nSuaidi M. T., Wong P. K., Mohd Tahir N. A., Chua E. W. Community Pharmacists' Knowledge, Attitude, and Practice in Providing Self-Care Recommendations for the Management of Premenstrual Syndrome // Medicina (Kaunas, Lithuania). – 2020. – V. 56, N 4. – Р. 181. https://doi.org/10.3390/medicina56040181\nAlmanasef M., Alqarni H. Self-care strategies for the management of primary dysmenorrhea among young women in Asir region, Saudi Arabia: a cross-sectional study // Eur. Rev. Med. Pharmacol. Sci. – 2023. – V. 27, N 1. – Р. 172–178. https://doi.org/10.26355/eurrev_202301_30869","source_license":"CC0","license_restricted":false}